AET Europe 2021: Powerful Engine for Therapeutic Antibody Discovery – RenMab/RenLite Immunoglobulin Humanized Mouse Platform

AET Europe 2021: Powerful Engine for Therapeutic Antibody Discovery – RenMab/RenLite Immunoglobulin Humanized Mouse Platform

Speaker: Dr. Li Hui, Ph.D., Scientific Director, Antibody Discovery

  • The most desired therapeutic antibodies will be the ones with the best developability and least immunogenicity. Human antibodies that are generated from immunoglobulin transgenic mice have been proven to be successful due to the in vivo natural selection, affinity maturation of antibody-secreting B cells.
  • Biocytogen established the first and second generation of immunoglobulin humanized mouse platforms: RenMab and RenLite. RenMab mice carry a full human heavy chain and kappa light chain repertoire and have been proven to be a robust human antibody discovery engine. RenLite mouse is designed to overcome the common challenge of bispecific antibody discovery: heavy and light chain mispairing while carrying a full human heavy chain repertoire diversity.
  • Both RenMab and RenLite mice can be further genetically modified by knocking out specific target genes to break immune tolerance and elicit strong responses for challenging and high homologous targets.

Share:

Please fill out the form below to request a download of this Webinar









You have successfully subscribed to the newsletter!

There was an error while trying to send your request. Please try again.

Biocytogen will use the information you provide on this form to be in touch with you and to provide updates and marketing.